Accessibility Menu

Myriad Genetics(FRA) MYD

Market Cap€255.48MMarket cap calculated using publicly traded shares outstanding only. Does not include unlisted, private, or dual-class non-traded shares. Implied market cap may vary.
Since IPO (1999)+11%
5 YearN/A
1 Year-4%
1 Month+37%
€2.72
+1.95%
+0.05Today
Myriad Genetics last closing stock price
MetricPriceDate
Last closeEUR 26.722022-08-11
Myriad Genetics stock price return by period
PeriodPrice returnPrice at period startPeriod start date
1 week+4.46%EUR 25.582022-08-04
1 month+37.17%EUR 19.482022-07-12
3 month+38.81%EUR 19.252022-05-13
Year to date+9.73%EUR 24.352021-12-30
1 year-4.16%EUR 27.882021-08-11
Since inception+10.72%EUR 2.411999-07-16

Myriad Genetics Financials at a Glance

Market Cap

€255.48MMarket cap calculated using publicly traded shares outstanding only. Does not include unlisted, private, or dual-class non-traded shares. Implied market cap may vary.

Revenue (TTM)

€691.58

Net Income (TTM)

-€96.54

EPS (TTM)

-€1.03

P/E Ratio

-2.60

Dividend

€0.00

Beta (Volatility)

0.07 (Low)

Price

€2.72

Volume

0

Open

€2.72

Previous Close

€2.67

Daily Range

€2.72 - €2.72

52-Week Range

€2.45 - €7.10

Estimated Earnings Date

N/A

MYD News

No articles available.

Motley Fool Moneyball Superscore

Our CEO Is Handing Members His Secret Weapon

It's called Motley Fool Moneyball, our new proprietary AI tool

We spent over half a million dollars in R&D to build a tool that makes stock research faster, sharper, and smarter. Our analysts use it every day, and now, you can too.

Get Access Now

About Myriad Genetics

Myriad Genetics, Inc. engages in the discovery, development, and marketing of transformative molecular diagnostic tests. It operates through the Diagnostics and Other segments. The Diagnostics segment provides testing and collaborative development of testing that is designed to assess an individual's risk of developing a disease later in life. The Other segment offers testing products and services to the pharmaceutical, biotechnology and medical research industries, research and development, and clinical services for patients, and also includes corporate services. The company was founded by Walter A. Gilbert, Mark H. Skolnick, and Peter D. Meldrum in May 1991 and is headquartered in Salt Lake City, UT.

Industry

Biotechnology

Employees

2,700

CEO

Samraat S Raha, MBA

MYD Financials

Key Financial Metrics (TTM)

Gross Margin

N/A

Operating Margin

N/A

Net Income Margin

N/A

Return on Equity

-32.37%

Return on Capital

N/A

Return on Assets

N/A

Earnings Yield

-38.46%

Dividend Yield

0.00%

Payout Ratio

N/A

Stock Overview

Market Cap

€255.48MMarket cap calculated using publicly traded shares outstanding only. Does not include unlisted, private, or dual-class non-traded shares. Implied market cap may vary.

Shares Outstanding

95.65M

Volume

0

Avg. Volume

186.909

Financials (TTM)

Gross Profit

N/A

Operating Income

N/A

EBITDA

N/A

Operating Cash Flow

N/A

Capital Expenditure

N/A

Free Cash Flow

N/A

Cash & ST Invst.

N/A

Total Debt

N/A

Myriad Genetics Performance Analysis

Myriad Genetics annual revenue and year-over-year revenue growth by fiscal year
Fiscal yearPeriod endRevenueYoY growth
20222022-12-31EUR 645,496,26910.5%
20232023-12-31EUR 696,687,7537.9%
20242024-12-31EUR 774,343,30911.1%
20252025-12-31EUR 730,565,398-5.7%
Myriad Genetics annual diluted earnings per share and year-over-year EPS growth by fiscal year
Fiscal yearPeriod endDiluted EPSYoY growth
20222022-12-31EUR -1.32348.2%
20232023-12-31EUR -2.94122.5%
20242024-12-31EUR -1.30-55.8%
20252025-12-31EUR -3.50169.5%

Revenue Growth Rate

Annual and quarterly growth comparison

Earnings Per Share Growth Rate

Annual and quarterly EPS growth comparison

Quarterly Performance

Name
Q2 2026YOY CHG

Revenue

€164.01

+0.9%

Gross Profit

€102.52

+0.8%

Gross Margin

62.51%

+0.9%

Market Cap

€255.48MMarket cap calculated using publicly traded shares outstanding only. Does not include unlisted, private, or dual-class non-traded shares. Implied market cap may vary.

N/A

Market Cap/Employee

€0.18

N/A

Employees

2,700

N/A

Net Income

-€37.15

+0.1%

EBITDA

-€22.62

-14.2%

Quarterly Fundamentals

Name
Q2 2026YOY CHG

Total Cash

€284.88

+46.0%

Total Debt

€184.12

+1.4%

Accounts Receivable

€95.78

+0.8%

Inventory

€26.76

+1.1%

Long Term Debt

€177.73

+2.4%

Short Term Debt

€6.39

+0.1%

Return on Assets

-17.00%

+0.4%

Return on Invested Capital

-24.87%

+1.7%

Free Cash Flow

-€9.06

+0.7%

Operating Cash Flow

-€7.22

+0.7%

Other Investments to Explore

People Also Watch

Symbol / CompanyPricePrice Chg
^GSPCS&P 500
$7,684.24-0.00%
^DJIDJI
$53,254.61-0.01%
^IXICNASDAQ
$26,319.55-0.00%
BTCBitcoin
$78,890.00-0.00%

Trending Stocks

Symbol / CompanyPricePrice Chg
WETOWetour Robotics
$5.48-0.04%
TQQQProShares Trust - ProShares UltraPro Qqq
$71.92+0.00%
INTCIntel
$89.51+0.00%
IBITiShares Bitcoin Trust
$44.67+0.02%

Questions About MYD

What is the current price of Myriad Genetics?

Myriad Genetics is trading at €2.72 per share.

What is the 52-week range for Myriad Genetics?

Over the past 52 weeks, Myriad Genetics has traded between €2.45 and €7.10.

How much debt does Myriad Genetics have?

As of the most recent reporting period, Myriad Genetics reported total debt of €184.12M.

How much cash does Myriad Genetics have on hand?

Myriad Genetics reported €100.76M in cash and cash equivalents in its most recent financial results.

What is Myriad Genetics’s dividend yield?

Myriad Genetics does not currently have a dividend yield.

Premium Investing Services

Invest better with The Motley Fool. Get stock recommendations, portfolio guidance, and more from The Motley Fool's premium services.